Financial news app Zhitong Finance learned that on August 16, HSI Limited announced the latest quarterly inspection results, and Mes Health (02415) was removed from the Hang Seng Composite Small-Cap Index. The change will be implemented after the close of trading on Friday, September 6, 2024, and will take effect on Monday, September 9, 2024. CITIC Securities research report pointed out that Mes Health may be removed from the Hong Kong stock connect due to reasons such as market cap decline, insufficient liquidity, or violation of relevant regulations.

In the secondary market, Mes Health's stock price continued to plummet this week, falling by more than 17%, and is currently trading at HKD 2.23. However, in terms of performance, Mes Health successfully achieved a turnaround from loss to profit in 2023. As of December 31, 2023, the annual revenue was CNY 0.349 billion, a year-on-year growth of 0.1%, with a net income of CNY 55.042 million, compared with a loss of CNY 99.881 million in the same period last year. Total revenue increased by 0.1% year-on-year during the period, mainly due to an increase in revenue from the physician platform solution.

Recently, Mes Health announced that its subsidiary, Shanghai Chungu Biomedical Technology Co., Ltd. (Biogu), has officially reached a strategic cooperation with Vita Group Co., Ltd. (Vita Group). The two parties will jointly stimulate more local innovation vitality through the co-construction of multiple alliances, such as the strategic service alliance for media promotion, park investment promotion, industry sharing exchange, market acceleration service, scientific research innovation alliance, and financial service innovation alliance. Deeply promote the influence of Vita Park and Vita Group's high-quality products, and help Vita Group's core competitiveness to continue to rise.